Variant fc domains and uses thereof
AssigneeCidara Therapeutics, Inc.
InventorLeslie W. TARI
Life of this patent
Estimating the term…
Abstract
This disclosure relates to variant Fc domain monomers, fusion proteins, conjugates, compositions, and related methods for treating or preventing disease. In particular, the invention features variant Fc domain monomers which include mutations at position 220, and 252, 254, and/or 256 or 309, 311, and/or 434 according to the Kabat Index numbering. The invention also features variant Fc domain monomers including mutations at position 220 according to the Kabat index number, wherein the variant Fc domain monomer is between 200 and 300 amino acid residues in length and/or is between about 20 kDa and about 40 kDa in mass.
Claims94
A variant Fc domain monomer, wherein the variant Fc domain monomer comprises substitutions at position 220 and positions 252, 254, and 256 or positions 309, 311, and 434, wherein numbering is according to the EU index as in Kabat, and wherein the substitution at position 220 is a serine, the substitution at position 252 is a tyrosine, the substitution at position at position 254 is a threonine, the substitution at position 256 is a glutamic acid, the substitution at position 309 is an aspartic acid, the substitution at position at position 311 is a histidine, and the substitution at position 434 is a serine.
A variant Fc domain monomer comprising a serine at amino acid position 220, wherein the amino acid numbering is according to the EU index as in Kabat, and wherein the variant Fc domain monomer is between 200 and 300 amino acid residues in length.
A variant Fc domain monomer comprising a serine at amino acid position 220, wherein the amino acid numbering is according to the EU index as in Kabat, and wherein the variant Fc domain monomer is between about 20 kDa and about 40 kDa in mass.
A conjugate comprising a variant Fc domain monomer and at least one therapeutic agent, wherein the variant Fc domain monomer is covalently conjugated to the therapeutic agent by a linker.
A fusion protein comprising a variant Fc domain monomer and at least one polypeptide therapeutic agent, wherein the variant Fc domain monomer is covalently conjugated to the polypeptide therapeutic agent by a linker.
Dependencies are inferred from the claim text.